$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer 원문보기

Communications biology, v.3 no.1, 2020년, pp.630 -   

Ku, Jayoung (Department of Chemical and Biomolecular Engineering and KAIST Institute for Health Science and Technology (KIHST), Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea) ,  Kim, Ryul (Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea) ,  Kim, Dongchan (Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea) ,  Kim, Daeyoon (Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea) ,  Song, Seulki (Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea) ,  Lee, Keonyong (Department of Chemical and Biomolecular Engineering and KAIST Institute for Health Science and Technology (KIHST), Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea) ,  Lee, Namseok (Department of Chemical and Biomolecular Engineering and KAIST Institute for Health Science and Technology (KIHST), Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Repu) ,  Kim, MinA ,  Yoon, Sung-Soo ,  Kwon, Nam Hoon ,  Kim, Sunghoon ,  Kim, Yoosik ,  Koh, Youngil

Abstract AI-Helper 아이콘AI-Helper

Aminoacyl-tRNA synthetase-interacting multifunctional protein 2 (AIMP2) is a non-enzymatic component required for the multi-tRNA synthetase complex. While exon 2 skipping alternatively spliced variant of AIMP2 (AIMP2-DX2) compromises AIMP2 activity and is associated with carcinogenesis, its clinical...

참고문헌 (43)

  1. 1. Kim JY p38 is essential for the assembly and stability of macromolecular tRNA synthetase complex: implications for its physiological significance Proc. Natl Acad. Sci. USA 2002 99 7912 7916 10.1073/pnas.122110199 12060739 

  2. 2. Kim S You S Hwang D Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping Nat. Rev. Cancer 2011 11 708 718 10.1038/nrc3124 21941282 

  3. 3. Choi JW Um JY Kundu JK Surh YJ Kim S Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis Carcinogenesis 2009 30 1638 1644 10.1093/carcin/bgp170 19622630 

  4. 4. Han JM AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53 Proc. Natl Acad. Sci. USA 2008 105 11206 11211 10.1073/pnas.0800297105 18695251 

  5. 5. Choi JW AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2 J. Cell Sci. 2009 122 2710 2715 10.1242/jcs.049767 19584093 

  6. 6. Yum MK AIMP2 controls intestinal stem cell compartments and tumorigenesis by modulating Wnt/beta-catenin signaling Cancer Res. 2016 76 4559 4568 10.1158/0008-5472.CAN-15-3357 27262173 

  7. 7. Choi JW Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis PLoS Genet. 2011 7 e1001351 10.1371/journal.pgen.1001351 21483803 

  8. 8. Choi JW Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer J. Mol. Cell Biol. 2012 4 164 173 10.1093/jmcb/mjs018 22532625 

  9. 9. Jo SM Rapid detection of exon 2-deleted AIMP2 mutation as a potential biomarker for lung cancer by molecular beacons Biosens. Bioelectron. 2013 46 142 149 10.1016/j.bios.2013.02.037 23537880 

  10. 10. Schwarzacher T DNA, chromosomes, and in situ hybridization Genome 2003 46 953 962 10.1139/g03-119 14663512 

  11. 11. Wang H Dual-color ultrasensitive bright-field RNA in situ hybridization with RNAscope Methods Mol. Biol. 2014 1211 139 149 10.1007/978-1-4939-1459-3_12 25218383 

  12. 12. Han JM Hierarchical network between the components of the multi-tRNA synthetase complex: implications for complex formation J. Biol. Chem. 2006 281 38663 38667 10.1074/jbc.M605211200 17062567 

  13. 13. Prokocimer M Molchadsky A Rotter V Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy Blood 2017 130 699 712 10.1182/blood-2017-02-763086 28607134 

  14. 14. Tessoulin B p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell Blood Rev. 2017 31 251 259 10.1016/j.blre.2017.03.001 28284458 

  15. 15. Tan G Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells Int. J. Cancer 2002 97 168 172 10.1002/ijc.1591 11774260 

  16. 16. Wahl AF Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis Nat. Med. 1996 2 72 79 10.1038/nm0196-72 8564846 

  17. 17. Grandela C Pera MF Grimmond SM Kolle G Wolvetang EJ p53 is required for etoposide-induced apoptosis of human embryonic stem cells Stem Cell Res. 2007 1 116 128 10.1016/j.scr.2007.10.003 19383392 

  18. 18. Jamil S Lam I Majd M Tsai SH Duronio V Etoposide induces cell death via mitochondrial-dependent actions of p53 Cancer Cell Int. 2015 15 79 10.1186/s12935-015-0231-z 26251638 

  19. 19. Kong B Wang Q Fung E Xue K Tsang BK p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers J. Biol. Chem. 2014 289 27134 27145 10.1074/jbc.M114.594812 25112877 

  20. 20. Schmid JO Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin Cancer Res. 2012 72 5824 5832 10.1158/0008-5472.CAN-12-1201 22962266 

  21. 21. Mody MD Gill HS Higgins KA Saba NF Kota VK Complete remission of acute myeloid leukemia following cisplatin based concurrent therapy with radiation for squamous cell laryngeal cancer Case Rep. Hematol. 2016 2016 8581421 27127664 

  22. 22. Lee YG Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide Eur. J. Haematol. 2014 92 478 484 10.1111/ejh.12274 24460733 

  23. 23. Kumar S Tchounwou PB Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells Oncotarget 2015 6 40734 40746 10.18632/oncotarget.5754 26486083 

  24. 24. Seiter K Katragadda S Ponce D Rasul M Ahmed N Temozolomide and cisplatin in relapsed/refractory acute leukemia J. Hematol. Oncol. 2009 2 21 10.1186/1756-8722-2-21 19463179 

  25. 25. Dohner H Weisdorf DJ Bloomfield CD Acute myeloid leukemia N. Engl. J. Med. 2015 373 1136 1152 10.1056/NEJMra1406184 26376137 

  26. 26. Sakamoto KM Targeting novel signaling pathways for resistant acute myeloid leukemia Mol. Genet. Metab. 2015 114 397 402 10.1016/j.ymgme.2014.11.017 25533111 

  27. 27. Lee HS Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression Biochem. J. 2013 454 411 416 10.1042/BJ20130550 23815603 

  28. 28. Oh AY Inhibiting DX2-p14/ARF interaction exerts antitumor effects in lung cancer and delays tumor progression Cancer Res. 2016 76 4791 4804 10.1158/0008-5472.CAN-15-1025 27302160 

  29. 29. Won YS Lee SW Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme J. Biotechnol. 2012 158 44 49 10.1016/j.jbiotec.2012.01.006 22285955 

  30. 30. Cripe LD Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation Leukemia 2002 16 799 812 10.1038/sj.leu.2402457 11986940 

  31. 31. Platanias LC Map kinase signaling pathways and hematologic malignancies Blood 2003 101 4667 4679 10.1182/blood-2002-12-3647 12623839 

  32. 32. Lee HJ Daver N Kantarjian HM Verstovsek S Ravandi F The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia Clin. Cancer Res. 2013 19 327 335 10.1158/1078-0432.CCR-12-2087 23209034 

  33. 33. Ikezoe T Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia Int. J. Cancer 2011 129 2512 2521 10.1002/ijc.25910 21207414 

  34. 34. Yatabe Y A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer J. Mol. Diagn. 2006 8 335 341 10.2353/jmoldx.2006.050104 16825506 

  35. 35. Martinez AE Lin L Dunphy CH Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry Arch. Pathol. Lab. Med. 2007 131 1084 1088 17616995 

  36. 36. Kim D TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions Genome Biol. 2013 14 R36 10.1186/gb-2013-14-4-r36 23618408 

  37. 37. Wilks C The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data Database 2014 2014 bau093 10.1093/database/bau093 25267794 

  38. 38. Anders S Pyl PT Huber W HTSeq?a Python framework to work with high-throughput sequencing data Bioinformatics 2015 31 166 169 10.1093/bioinformatics/btu638 25260700 

  39. 39. Love MI Huber W Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 Genome Biol. 2014 15 550 10.1186/s13059-014-0550-8 25516281 

  40. 40. Luo W Friedman MS Shedden K Hankenson KD Woolf PJ GAGE: generally applicable gene set enrichment for pathway analysis BMC Bioinformatics 2009 10 161 10.1186/1471-2105-10-161 19473525 

  41. 41. Kanehisa M Goto S Kawashima S Okuno Y Hattori M The KEGG resource for deciphering the genome Nucleic Acids Res. 2004 32 D277 D280 10.1093/nar/gkh063 14681412 

  42. 42. Grimwade D Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials Blood 2010 116 354 365 10.1182/blood-2009-11-254441 20385793 

  43. 43. Li H The sequence alignment/map format and SAMtools Bioinformatics 2009 25 2078 2079 10.1093/bioinformatics/btp352 19505943 

LOADING...

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

유발과제정보 저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로